CHMP vouches for Ascendis Pharma's growth hormone for children

Ascendis Pharma is one step closer to launching its first drug in the EU, the growth hormone Skytrofa, as the EMA's expert committee, the CHMP, has given its positive recommendation for the treatment for children.
Photo: Kevin Grønnemann
Photo: Kevin Grønnemann
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Children and adolescents aged 3 to 18 years old with growth hormone deficiency (GHD) should be able receive treatment with Ascendis Pharma's growth hormone Skytrofa, says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading